Docoh
Loading...

AZN Astrazeneca

 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of April 2020
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Result of AGM
 
 
29 April 2020 16:00 BST
 
Results of Annual General Meeting held on 29 April 2020
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
 
 
RESOLUTION
 
VOTES FOR
 
% OF VOTES CAST
 
VOTES AGAINST
 
% OF VOTES CAST
 
VOTES CAST IN TOTAL
 
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
 
VOTES WITHHELD
 
1     
 
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019
 
 
1,061,180,10199.92872,2150.081,062,052,31680.93%7,121,452
2
 
To confirm dividends
 
 
1,058,995,78699.109,598,5310.901,068,594,31781.43%579,469
3
 
To reappoint PricewaterhouseCoopers LLP as Auditor
 
 
1,068,300,23599.97312,4490.031,068,612,68481.43%560,776
4
 
To authorise the Directors to agree the remuneration of the Auditor
 
 
1,067,398,62899.901,086,8580.101,068,485,48681.42%687,961
5a
 
To re-elect Leif Johansson as a Director
 
 
1,065,113,16799.693,276,0710.311,068,389,23881.42%784,805
5b
 
To re-elect Pascal Soriot as a Director
 
 
1,067,248,72399.901,033,1240.101,068,281,84781.41%892,364
5c
 
To re-elect Marc Dunoyer as a Director
 
 
1,060,164,24299.258,056,2650.751,068,220,50781.40%952,979
5d
 
To re-elect Geneviève Berger as a Director
 
 
882,846,92083.06179,994,84816.941,062,841,76880.99%6,331,650
5e
 
To re-elect Philip Broadley as a Director
 
 
1,066,048,99299.792,190,7050.211,068,239,69781.41%933,713
5f
 
To re-elect Graham Chipchase as a Director
 
 
1,062,682,50799.485,520,9360.521,068,203,44381.40%969,967
5g
 
To elect Michel Demaré as a Director
 
 
1,066,252,25999.821,969,5930.181,068,221,85281.40%951,558
5h
 
To re-elect Deborah DiSanzo as a Director
 
 
1,067,836,36299.97351,0910.031,068,187,45381.40%985,957
5i
 
To re-elect Sheri McCoy as a Director
 
 
1,064,329,86299.643,890,3680.361,068,220,23081.40%951,792
5j
 
To re-elect Tony Mok as a Director
 
1,067,117,37099.901,066,6690.101,068,184,03981.40%989,371
5k
 
To re-elect Nazneen Rahman as a Director
 
 
1,067,376,96399.92821,4670.081,068,198,43081.40%973,592
5l
 
To re-elect Marcus Wallenberg as a Director
 
 
955,082,66589.42113,060,72510.581,068,143,39081.40%1,030,019
6
 
To approve the Annual Report on Remuneration for the year ended 31 December 2019
 
 
1,032,308,14596.6535,747,7833.351,068,055,92881.39%1,118,038
7
 
To approve the Directors' Remuneration Policy
 
 
972,774,74294.7154,292,3765.291,027,067,11878.27%42,106,679
8
 
To authorise limited political donations
 
 
1,038,907,15297.7523,872,4002.251,062,779,55280.99%6,394,668
9
 
To authorise the Directors to allot shares
 
 
910,654,65085.26157,472,09314.741,068,126,74381.40%1,046,979
10
 
To authorise the Directors to disapply pre-emption rights
 
 
1,058,066,97299.238,200,3380.771,066,267,31081.26%2,906,339
11
 
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
 
 
1,054,711,67798.9211,513,4141.081,066,225,09181.25%2,948,557
12
 
To authorise the Company to purchase its own shares
 
 
1,051,131,06098.4116,950,8001.591,068,081,86081.39%1,091,896
13
 
To reduce the notice period for general meetings
 
 
998,062,80593.4470,101,5536.561,068,164,35881.40%1,008,865
14
 
To approve the 2020 Performance Share Plan
 
1,010,149,49195.6645,877,3964.341,056,026,88780.48%13,147,356
 
Issued capital
As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 AstraZeneca PLC
 
 
Date: 29 April 2020
 
 By: /s/ Adrian Kemp
 Name: Adrian Kemp
 Title: Company Secretary